BIOTRON LIMITED — Capital/Financing Update 2017

Jun 8, 2017

==> picture [32 x 35] intentionally omitted <==

==> picture [54 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [35 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

9 June 201 7

The Mana g er Compa n ies ASX Limi t ed 20 Bridge S treet Sydney N S W 2000

(2 pages by email)

Dear Mad a m

LYNX FINANCIAL APPOINTED AS CORPORATE ADVISOR TO ADVANCE COMMERCIALISATION STRATEGY IN CHINA

Sydney, Australia, 9 June 2017 – Biotron Limited ( A SX:BIT, B iotron or C ompany) is pleased t o announce t he appoin t ment of leading Sha n ghai base d advisory group, Ly n x Financi a l (HK) Lt d (Lynx Fin a ncial) as corporate a dvisor to assist the Company with the e xecution o f its Chin a commercia l isation str a tegy.

Lynx Fina n cial will s u pport Bio t ron in ide n tifying an d negotiating with sui ta ble partn e rs to enabl e the licensi n g of the C ompany’s antiviral d r ug platfor m in the People’s Re p ublic of C hina. Lyn x Financial h as a strong focus on China’s rapi d ly growin g healthcar e sector an d a particular strength i n cross boar d er transact i ons, facilit a ted by offi c es in Shanghai, San D iego and T el Aviv.

Biotron’s M anaging D irector, Dr Michelle M iller noted “The Com p any belie v es there is a significa n t opportunit y to execu t e a regio n al licensin g agreeme n t for its a ntiviral dr u g platfor m in Chin a . Respirator y and emer g ing viruse s are an is s ue in Chin a as in the rest of the world, and Hepatitis C virus (HC V ) remains a significan t problem i n the regio n .”

Managing D irector of Lynx Fina n cial, Mr D onald Xu said “ We a r e very exc i ted to be w orking wit h Biotron; C h ina is no w the seco n d largest pharmaceu t ical mark e t in the w o rld and g r owing at a significant rate. We b elieve Bi o tron’s ant i viral platf o rm repres e nts a stro n g regional partnerin g opportunit y here in C hina and w e look fo r ward to a s sisting the company in executi n g its Chin a strategy”.

Yours sinc e rely

==> picture [55 x 60] intentionally omitted <==

==> picture [39 x 60] intentionally omitted <==

Peter J. Ni g htingale Company S ecretary pjn8945

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for both HIV-1 and HCV and also has several earlier stage preclinical and research programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller Managing Director Biotron Limited +61-2 9805 0488 +61-(0)412313329

Rudi Michelson Monsoon Communications +61-3 9620 3333

2